You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Boehringer Ingelheim
AstraZeneca
Baxter
Merck

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

FLORBETABEN F-18 - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for florbetaben f-18 and what is the scope of patent protection?

Florbetaben f-18 is the generic ingredient in one branded drug marketed by Life Molecular and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Florbetaben f-18 has thirty-four patent family members in twenty-six countries.

One supplier is listed for this compound.

Summary for FLORBETABEN F-18
International Patents:34
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 1
Clinical Trials: 15
Patent Applications: 9
DailyMed Link:FLORBETABEN F-18 at DailyMed
Recent Clinical Trials for FLORBETABEN F-18

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of PennsylvaniaEarly Phase 1
Central Hospital, Nancy, FrancePhase 2/Phase 3
Seoul National University HospitalPhase 3

See all FLORBETABEN F-18 clinical trials

Pharmacology for FLORBETABEN F-18

US Patents and Regulatory Information for FLORBETABEN F-18

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Life Molecular NEURACEQ florbetaben f-18 SOLUTION;INTRAVENOUS 204677-001 Mar 19, 2014 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for FLORBETABEN F-18

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2213652 C02213652/01 Switzerland   Start Trial PRODUCT NAME: FLORBETABEN (18F); REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66210 23.08.2017
2213652 92647 Luxembourg   Start Trial PRODUCT NAME: FLORBETABEN (18F). FIRST REGISTRATION: 20140224
2213652 CR 2015 00018 Denmark   Start Trial PRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906/001 20140224
2213652 1590005-3 Sweden   Start Trial PRODUCT NAME: FLORBETABEN (18F); REG. NO/DATE: EU/1/13/906 20140224
2213652 8/2015 Austria   Start Trial PRODUCT NAME: FLORBETABEN (18 F); REGISTRATION NO/DATE: EU/1/13/906/001 (MITTEILUNG) 20140224
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Medtronic
Dow
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.